Stock Markets April 27, 2026 06:11 AM

Deutsche Bank Lowers Rating on Thyssenkrupp Nucera After Profit Warning and Slumping gH2 Orders

Bank trims price target and cites weak near-term green-hydrogen order pipeline following mid-March volatility

By Marcus Reed
Deutsche Bank Lowers Rating on Thyssenkrupp Nucera After Profit Warning and Slumping gH2 Orders

Deutsche Bank downgraded Thyssenkrupp Nucera to 'hold' from 'buy' and cut its price target to €10 from €11 after a mid-March profit warning materially reset near-term earnings expectations for the German electrolyser maker. The bank highlighted a weak green-hydrogen (gH2) order pipeline and now expects no further major gH2 order wins in fiscal 2025 and 2026, while the stock fell more than 3% on the news.

Key Points

  • Deutsche Bank downgraded Thyssenkrupp Nucera from "buy" to "hold" and cut its price target to €10 from €11.
  • A mid-March profit warning materially reset near-term earnings expectations for the electrolyser maker, according to the bank.
  • Deutsche Bank expects no further major green-hydrogen (gH2) order wins in fiscal 2025 and 2026, and the stock fell over 3% on the news.

Deutsche Bank moved Thyssenkrupp Nucera AG & Co. KGaA (ETR:NCH2) from a "buy" recommendation to a "hold" on Monday and lowered its price objective to €10 from €11. The change followed a profit warning in mid-March that the bank says materially altered expectations for near-term earnings at the German electrolyser manufacturer.

The downgrade came after a concentrated period of company announcements in mid-March that Deutsche Bank characterized as turbulent. Those events included a severe profit warning, the announcement of a project win with Moeve, and the initiation of a front-end engineering and design (FEED) study in India. Analyst Michael Kuhn framed the rating action as a reaction to that string of developments.

"While the shares have traded sideways recently, the profit warning has materially reset near-term earnings expectations," Kuhn said.

At the heart of Deutsche Bank's concern is what it describes as a weak pipeline for green-hydrogen orders, commonly referred to in the industry as gH2. As a result of that assessment, the bank now anticipates no further major gH2 order wins for Thyssenkrupp Nucera in fiscal years 2025 and 2026.

Market reaction was immediate: shares of the company fell by more than 3% on the day the downgrade was announced. Deutsche Bank's revised outlook positions the stock as offering a balanced risk-return profile in the absence of concrete evidence of a sustained pickup in gH2 order momentum.

The bank's stance emphasizes the linkage between order visibility for green-hydrogen projects and short-term earnings expectations for an electrolyser maker. Until there is tangible proof of renewed large-scale gH2 contracting, the analyst view is cautious.


Context and implications

  • Deutsche Bank's rating move reflects a reassessment of near-term earnings after a mid-March profit warning and related corporate developments.
  • The bank cited a weak gH2 order pipeline and is not forecasting major order wins for fiscal 2025 and 2026.
  • Shares reacted negatively, declining by over 3% on the downgrade news.

What the analyst said

Michael Kuhn noted the company's recent run of newsflow and emphasized that the profit warning had a material impact on short-term earnings expectations. He concluded that the stock offers a balanced risk-return profile until there is clear evidence of a sustained recovery in gH2 order activity.

Risks

  • Weak pipeline for green-hydrogen (gH2) orders may continue to pressure near-term revenue and earnings - this affects the clean-energy and industrial equipment sectors.
  • Absence of tangible proof of a sustained recovery in gH2 order momentum could keep investor sentiment muted - impacting capital markets and the company's stock performance.
  • Recent profit warning has materially lowered near-term earnings expectations, creating uncertainty for short-term operational and financial planning.

More from Stock Markets

U.S. Futures Mixed Ahead of Heavy Week; Verizon, Qualcomm Gain While GE Vernova Falls Apr 27, 2026 Medtronic Says Cyberattack Limited to Corporate IT, No Impact on Devices or Patient Care Apr 27, 2026 Suja Life launches IPO roadshow, sets price range at $21-$24 per share Apr 27, 2026 Sagimet Shares Jump 30% After Company Announces U.S. Phase 3 Plans for Acne Drug Apr 27, 2026 HawkEye 360 Sets IPO Range That Implies Up to $2.42 Billion Valuation Apr 27, 2026